조사회사 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2024년10월
AI in Biotechnology Market – Global Forecast to 2029
생명공학 시장의 AI – 기능 (의약품 설계 및 최적화, 바이오 마커, SAR, 임상 시험 설계, 데이터 평가, RWE, 재고, 공급망, 물류, 상시, 가격 설정, 환자 참여, 부작용) 및 최종 사용자 – 2029 년까지 세계 예측
Al in Biotechnology Market by Function (Drug Design & Optimisation, Biomarker, SAR; Clinical Trial Design, Data Assessment, RWE, Inventory, Supply chain, Logistics; Launch, Pricing, Patient Engagement, Adverse Events), & End User – Global Forecast to 2029
| 페이지 수 | 386 |
| 도표 수 | 514 |
| 가격 | |
| Single User License | USD 4,950 |
| Multi User License | USD 6,650 |
| Corporate License | USD 8,150 |
| Enterprise License | USD 10.000 |
| 구성 | 영문조사보고서 |
Report Overview
The global AI in biotechnology market is projected to reach USD 7.75 billion by 2029 from USD 3.23 billion in 2024, at a high CAGR of 19.1% during the forecast period.
생명공학의 세계 AI 시장은 예측 기간 동안 19.1%라는 높은 CAGR로 2024년 32억 3,000만 달러에서 2029년까지 77억 5,000만 달러에 이를 것으로 예측되고 있습니다.
The market is expected to grow as a result of the increasing demand for personalized therapies and precision medicines, and the growing applications of AI in epidemiological models for predicting disease outbreaks. It helps public health officials to respond and develop better vaccines which further drives market growth. The increasing demand for personalized therapies and precision medicine has led to an increasing number of clinical trials performed. For instance, as of October 2023, around 1584 clinical trials performed using AI for various diseases were reported to Clincaltrials.gov. However, the limited interpretability of AI algorithms, high implementation cost and data privacy & security concerns are some of the restraining factors for the market growth.
“Based on function, research & development segment dominated the AI in biotechnology market in 2023”
The AI in biotechnology market by function is broadly divided into six segments: research & development, regulatory compliance, manufacturing & supply chain, launch & commercial, and post-market surveillance & patient support. The research & development segment accounted for the largest share of the global AI in biotechnology market in 2023. The large share of this segment can be attributed to the rising demand for personalized medicine, automation in labs, the rise of predictive analytics, and the need for faster drug discovery. an increase in the number of AI-discovered molecules in clinical trials significantly augments market growth. For instance, AI-native Biotechs and their partners in the pharmaceutical industry have entered an increasing number of molecules for AI-driven clinical trials (Source: Elsevier B.V.). In 2023, there were around 67 reported ongoing trials, and this number has increased from 2014 with around 60% year-over-year compound growth.
“In 2023, the pharmaceutical companies held the largest market share among end users.”
Based on end user, pharmaceutical companies hold the largest share of the AI in biotechnology market. There are emerging health problems, notably cognitive decline that led to high healthcare services and medication demands, associated with such demographic shifts. Pharmaceutical companies will experience huge growth opportunities as life expectancy increases, thereby raising the increasing healthcare demands of this aging population. Additionally, massive investments are being made by pharmaceutical companies into research and development, particularly drug discovery and development processes wherein AI is utilized for tasks like target identification, lead optimization, and patient stratification in clinical trials.
“In 2023, Europe was the second largest regional market for AI in the biotechnology market.”
In 2023, Europe held the second-highest share of the AI in biotechnology market. This dominance is attributed to a substantial increase in investment in Europe for AI, with a growing number of patent filings for biotechnology-related medical technology. In the year 2022, the European Patent Office (EPO) published over 10,000 AI patent applications, which highlights an increased focus on AI solutions in biotechnology. In March 2023, the UK government pledged investment in nine promising AI healthcare technologies to speed up research and development. Moreover, in August 2023, the government launched 22 new projects to explore the application of AI in healthcare. All these initiatives represent Europe’s determination to spearhead applications of AI in the biotechnology sector.
The break-down of primary participants is as mentioned below:
- By Company Type – Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation – C-level: 42%, Director-level: 31%, and Others: 27%
- By Region – North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%
NVIDIA Corporation (US), Illumina, Inc. (US), Exscientia plc (UK), Schrödinger, Inc. (US), Recursion Pharmaceuticals, Inc. (US), SOPHiA GENETICS (Switzerland), Predictive Oncology. (US), Deep Genomics. (Canada), ), Data4Cure, Inc. (US), Genoox (US), BenevolentAI (US), and DNAnexus, Inc. (US) are some of the key players in the AI in biotechnology market.
The study includes an in-depth competitive analysis of these key players in AI in biotechnology market, with their company profiles, recent developments, and key market strategies.
Research Coverage:
The report analyses the AI in biotechnology market. It aims to estimate the market size and future growth potential of various market segments based on offering (end-to-end solutions, niche solutions, technology providers, and services), function (research & development [R&D], regulatory compliance, manufacturing & supply chain, launch & commercial, post-market surveillance & patient support, and corporate), deployment mode (cloud-based, and on-premise), end-user (pharmaceutical companies, biotechnology companies, research institutes and labs, healthcare providers, and contract research organizations [CRO]), and region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in biotechnology market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, collaborations, acquisitions, expansion, agreements, investment, and product launches associated with the AI in biotechnology market. Competitive analysis of upcoming startups in the AI in biotechnology market ecosystem is covered in this report.
Reasons to Buy the Report
This report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
Analysis of key drivers: (growing cross-industry collaborations and partnerships, growing need to reduce the time and cost of drug discovery and development, rising adoption of AI in precision medicine, improving computing power, and declining hardware cost), restraints (high implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies, data privacy risks and compliance challenges for AI in biotechnology), opportunities (integrating AI and big data in precision medicine for biotechnology advancement, surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations, innovation across healthcare, agriculture, and environmental science for global growth), and challenges (data quality and interpretability issues that hinder AI integration and trustworthiness, AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges) influencing the growth of the AI in biotechnology market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the AI in biotechnology market.
- Market Development: Comprehensive information on the lucrative emerging markets, by offering, function, deployment mode, end-user, and region.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in biotechnology market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in biotechnology market including NVIDIA Corporation (US), Illumina, Inc. (US), Exscientia (UK), Schrödinger, Inc. (US), Recursion Pharmaceuticals, Inc. (US), SOPHiA GENETICS (Switzerland), Predictive Oncology. (US),Deep Genomics. (Canada), Exscientia (US), and Data4Cure, Inc.
Table of Contents
1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.3 STUDY SCOPE 38
1.3.1 MARKETS COVERED & REGIONAL SCOPE 38
1.3.2 INCLUSIONS & EXCLUSIONS 39
1.3.3 YEARS CONSIDERED 40
1.4 CURRENCY CONSIDERED 40
1.5 LIMITATIONS 41
1.6 STAKEHOLDERS 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
2.1.1 SECONDARY DATA 44
2.1.1.1 Key data from secondary sources 45
2.1.2 PRIMARY DATA 45
2.1.2.1 Key data from primary sources 47
2.1.2.2 Insights from primary experts 48
2.2 MARKET SIZE ESTIMATION 49
2.3 DATA TRIANGULATION 53
2.4 MARKET SHARE ESTIMATION 54
2.5 RESEARCH ASSUMPTIONS 54
2.6 LIMITATIONS 54
2.6.1 METHODOLOGY-RELATED LIMITATIONS 54
2.6.2 SCOPE-RELATED LIMITATIONS 54
2.7 RISK ASSESSMENT 55
3 EXECUTIVE SUMMARY 56
4 PREMIUM INSIGHTS 60
4.1 AI IN BIOTECHNOLOGY MARKET OVERVIEW 60
4.2 AI IN BIOTECHNOLOGY MARKET, BY REGION 61
4.3 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER & REGION 62
4.4 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHIC SNAPSHOT 63
4.5 AI IN BIOTECHNOLOGY MARKET: DEVELOPED VS. EMERGING ECONOMIES 63
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 65
5.2.1.1 Growing cross-industry collaborations and partnerships 65
5.2.1.2 Growing need to reduce time and cost of drug discovery and development 66
5.2.1.3 Rising adoption of AI in precision medicine 66
5.2.1.4 Improving computing power and declining hardware cost 67
5.2.2 RESTRAINTS 68
5.2.2.1 High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies 68
5.2.2.2 Data privacy risks and compliance challenges for AI in biotechnology 68
5.2.3 OPPORTUNITIES 68
5.2.3.1 Integrating AI and big data in precision medicine for biotechnology advancement 68
5.2.3.2 Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations 69
5.2.3.3 Innovation across healthcare, agriculture, and environmental science for global growth 69
5.2.4 CHALLENGES 70
5.2.4.1 Data quality and interpretability issues that hinder AI integration and trustworthiness 70
5.2.4.2 AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges 70
5.3 ECOSYSTEM ANALYSIS 71
5.4 CASE STUDY ANALYSIS 72
5.4.1 LEVERAGED NVIDIA DGX CLOUD FOR RAPID TRAINING OF PROTEIN MODELS 72
5.4.2 IMPLEMENTED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION 73
5.4.3 ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS 73
5.5 VALUE CHAIN ANALYSIS 74
5.6 PORTER’S FIVE FORCES ANALYSIS 75
5.6.1 BARGAINING POWER OF SUPPLIERS 76
5.6.2 BARGAINING POWER OF BUYERS 76
5.6.3 THREAT OF SUBSTITUTES 76
5.6.4 THREAT OF NEW ENTRANTS 76
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 76
5.7 REGULATORY ANALYSIS 77
5.7.1 REGULATORY LANDSCAPE 77
5.7.1.1 North America 77
5.7.1.2 Europe 78
5.7.1.3 Asia Pacific 79
5.7.1.4 Latin America 80
5.7.1.5 Middle East & Africa 80
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.8 PATENT ANALYSIS 83
5.8.1 PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY 83
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 84
5.9 TECHNOLOGY ANALYSIS 87
5.9.1 KEY TECHNOLOGIES 87
5.9.1.1 Natural Language Processing (NLP) 87
5.9.1.2 Predictive analytics 87
5.9.2 COMPLEMENTARY TECHNOLOGIES 87
5.9.2.1 Cloud computing 87
5.9.2.2 Big data analytics 87
5.10 INDUSTRY TRENDS 88
5.10.1 EVOLUTION OF AI IN BIOTECHNOLOGY 88
5.10.2 COMPUTER-AIDED DRUG DESIGN AND AI 89
5.11 PRICING ANALYSIS 89
5.11.1 INDICATIVE PRICING ANALYSIS, BY DRUG DISCOVERY PROCESS 90
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION 90
5.12 KEY CONFERENCES & EVENTS, 2024–2025 91
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 92
5.13.1 BUYING CRITERIA 93
5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
5.15 END-USER ANALYSIS 95
5.15.1 UNMET NEEDS 95
5.15.2 END-USER EXPECTATIONS 96
5.16 INVESTMENT & FUNDING SCENARIO 96
5.17 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET 97
5.17.1 KEY USE CASES 98
5.17.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 98
5.17.2.1 Case study: Accelerated biomarker discovery and clinical trial optimization 98
5.17.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 99
5.17.3.1 Drug discovery and development market 99
5.17.3.2 Genomics and bioinformatics market 99
5.17.3.3 Medical imaging & diagnostics market 100
5.17.4 USER READINESS & IMPACT ASSESSMENT 100
5.17.4.1 User readiness 100
5.17.4.1.1 Pharmaceutical companies 100
5.17.4.1.2 Biotechnology companies 100
5.17.4.2 Impact assessment 101
5.17.4.2.1 User A: Pharmaceutical companies 101
5.17.4.2.1.1 Implementation 101
5.17.4.2.1.2 Impact 101
5.17.4.2.2 User B: Biotechnology companies 101
5.17.4.2.2.1 Implementation 101
5.17.4.2.2.2 Impact 101
6 AI IN BIOTECHNOLOGY MARKET, BY OFFERING 102
6.1 INTRODUCTION 103
6.2 END-TO-END SOLUTIONS 103
6.2.1 GROWING USE OF ADVANCED ALGORITHMS TO IMPROVE PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH 103
6.3 NICHE SOLUTIONS 104
6.3.1 ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION 104
6.4 TECHNOLOGIES 105
6.4.1 ABILITY OF TECHNOLOGIES TO ENHANCE DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH 105
6.5 SERVICES 106
6.5.1 CONSULTING SERVICES 107
6.5.1.1 Increasing efficiency of research processes and cost savings to boost adoption of consulting services 107
6.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT 108
6.5.2.1 Increasing precision and efficiency in IT support services to boost demand 108
6.5.3 TRAINING & EDUCATION SERVICES 108
6.5.3.1 Need for skilled talent to drive market growth 108
6.5.4 POST-SALES & MAINTENANCE SERVICES 109
6.5.4.1 Complexity of AI systems and need for improvement in AI algorithms to boost market 109
7 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 111
7.1 INTRODUCTION 112
7.2 RESEARCH & DEVELOPMENT 112
7.2.1 DRUG DISCOVERY 114
7.2.1.1 Molecular design & optimization 115
7.2.1.1.1 Increased efficiency in drug discovery with molecular design & optimization to drive market growth 115
7.2.1.2 Biomarker discovery 116
7.2.1.2.1 Ability to analyze large data sets with AI-enabled biomarker discovery to boost demand for 116
7.2.1.3 Structure-activity relationship (SAR) modeling 117
7.2.1.3.1 Improved data analysis, predictive modeling, and compound optimization for drug candidates with SAR to fuel growth 117
7.2.2 CLINICAL DEVELOPMENT 117
7.2.2.1 Trial design 119
7.2.2.1.1 Ability of AI to improve trial design through simulations and patient stratification to favor market 119
7.2.2.2 Site selection 119
7.2.2.2.1 Optimized process of selecting clinical trial sites to fuel growth 119
7.2.2.3 Recruitment 120
7.2.2.3.1 Enhanced process of selecting and enrolling participants for clinical trials to drive demand 120
7.2.2.4 Clinical data assessment 121
7.2.2.4.1 Ability of clinical data assessment to enhance efficiency and accuracy of data interpretation to propel market 121
7.2.2.5 Predictive toxicity & risk monitoring 121
7.2.2.5.1 Ability of data integration and predictive modeling to create comprehensive risk profiles for drug candidates to support market 121
7.2.2.6 Monitoring & drug adherence 122
7.2.2.6.1 Enhanced patient compliance with monitoring & drug adherence to drive market growth 122
7.2.2.7 Real-world evidence (RWE) analysis 123
7.2.2.7.1 Enhanced safety monitoring & economic evaluation with RWE analysis to propel growth 123
7.3 REGULATORY COMPLIANCE 123
7.3.1 ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH 123
7.4 MANUFACTURING & SUPPLY CHAIN 124
7.4.1 SUPPLY CHAIN PLANNING 126
7.4.1.1 Increasing demand for real-time data analytics to accelerate market growth 126
7.4.2 INVENTORY MANAGEMENT 126
7.4.2.1 Automating stock tracking and replenishment with advanced analytics to fuel growth 126
7.4.3 LOGISTICS OPTIMIZATION 127
7.4.3.1 Ability of AI to drive collaboration and transparency in biotechnology logistics to aid growth 127
7.4.4 DEMAND FORECASTING 128
7.4.4.1 Ability to integrate data for reliable demand forecasts to fuel growth 128
7.4.5 PREDICTIVE MAINTENANCE 128
7.4.5.1 Boosting equipment reliability with AI-powered predictive maintenance to drive demand 128
7.4.6 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS 129
7.5 LAUNCH & COMMERCIAL 130
7.5.1 LAUNCH COORDINATION 131
7.5.1.1 Growing product launch success rates through predictive analytics to boost adoption 131
7.5.2 PATIENT ENGAGEMENT 131
7.5.2.1 Advantages such as real-time patient feedback for better health outcomes to support growth 131
7.5.3 MARKETING OPERATIONS 132
7.5.3.1 Enhanced marketing performance with AI to boost market 132
7.5.4 PREDICTIVE PRICING 133
7.5.4.1 Ability of AI to enhance pricing accuracy to drive adoption 133
7.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT 133
7.6.1 MEDICATION ADHERENCE 134
7.6.1.1 Growing demand for personalized healthcare to drive market 134
7.6.2 ADVERSE EVENT REPORTING 135
7.6.2.1 Advantages such as faster post-market surveillance and enhanced drug safety to drive demand 135
7.6.3 PATIENT MONITORING 136
7.6.3.1 Rise of remote healthcare solutions to boost demand 136
7.6.4 COMPLIANCE MONITORING 136
7.6.4.1 Increasing complexity of regulatory requirements to drive adoption 136
7.6.5 PATIENT SUPPORT PROGRAMS 137
7.6.5.1 Growing interest in patient-centered care to support growth 137
7.7 CORPORATE 138
7.7.1 RISK MANAGEMENT 139
7.7.1.1 Rising expenditure for drug development to support growth 139
7.7.2 COMPLIANCE MONITORING 139
7.7.2.1 Strict guidelines from bodies to aid growth 139
7.7.3 SALES FORCE OPTIMIZATION 140
7.7.3.1 Need for data-driven decision-making to boost adoption of sales force optimization 140
7.7.4 OTHER CORPORATE FUNCTIONS 141
8 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 142
8.1 INTRODUCTION 143
8.2 CLOUD-BASED SOLUTIONS 143
8.2.1 PUBLIC CLOUD 144
8.2.1.1 Need to reduce dependency on expensive on-premise infrastructure to boost demand 144
8.2.2 PRIVATE CLOUD 145
8.2.2.1 Need for enhanced security and data protection to drive market growth 145
8.2.3 MULTI-CLOUD 146
8.2.3.1 Enhanced flexibility & cost optimization to support market growth 146
8.2.4 HYBRID CLOUD 147
8.2.4.1 Cost efficiency and flexibility of hybrid cloud to fuel growth 147
8.3 ON-PREMISE SOLUTIONS 148
8.3.1 ADVANTAGES SUCH AS DATA SECURITY AND PRIVACY AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH 148
9 AI IN BIOTECHNOLOGY MARKET, BY END USER 150
9.1 INTRODUCTION 151
9.2 PHARMACEUTICAL COMPANIES 151
9.2.1 INNOVATION AND EFFICIENCY ASSOCIATED WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION 151
9.3 BIOTECHNOLOGY COMPANIES 152
9.3.1 ABILITY OF AI-DRIVEN INNOVATIONS TO ACCELERATE PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT GROWTH 152
9.4 RESEARCH INSTITUTES & LABS 153
9.4.1 STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS 153
9.5 HEALTHCARE PROVIDERS 154
9.5.1 IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION 154
9.6 CONTRACT RESEARCH ORGANIZATIONS (CROS) 155
9.6.1 ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH 155
10 AI IN BIOTECHNOLOGY MARKET, BY REGION 157
10.1 INTRODUCTION 158
10.2 NORTH AMERICA 159
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 165
10.2.2 US 165
10.2.2.1 Increasing investments and partnerships to drive market 165
10.2.3 CANADA 171
10.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market 171
10.3 EUROPE 177
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 184
10.3.2 GERMANY 184
10.3.2.1 Increased funding in start-ups to drive uptake of AI in biotechnology 184
10.3.3 UK 190
10.3.3.1 Increasing investments and government fund allocations to drive market 190
10.3.4 FRANCE 195
10.3.4.1 Government initiatives in France to support market growth 195
10.3.5 ITALY 201
10.3.5.1 Growing investments to create opportunities for market growth 201
10.3.6 SPAIN 207
10.3.6.1 Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market 207
10.3.7 REST OF EUROPE 212
10.4 ASIA PACIFIC 218
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 226
10.4.2 JAPAN 226
10.4.2.1 Accelerating AI-driven drug discovery and biotechnology innovation to drive market in Japan 226
10.4.3 CHINA 232
10.4.3.1 Rising foreign investments to drive market in China 232
10.4.4 INDIA 238
10.4.4.1 Increasing number of start-ups and support from government to propel market 238
10.4.5 SOUTH KOREA 244
10.4.5.1 Significant advances in AI integration for R&D to fuel growth 244
10.4.6 REST OF ASIA PACIFIC 250
10.5 LATIN AMERICA 256
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 262
10.5.2 BRAZIL 262
10.5.2.1 Funding of biotech companies to drive market in Brazil 262
10.5.3 MEXICO 268
10.5.3.1 Investment inflows and strengthening AI-related education to drive market in Mexico 268
10.5.4 REST OF LATIN AMERICA 274
10.6 MIDDLE EAST & AFRICA 280
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 286
10.6.2 GCC COUNTRIES 286
10.6.2.1 Increase in healthcare investments to support market growth 286
10.6.3 REST OF MIDDLE EAST & AFRICA 293
11 COMPETITIVE LANDSCAPE 300
11.1 INTRODUCTION 300
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 300
11.3 REVENUE ANALYSIS, 2019–2023 302
11.4 MARKET SHARE ANALYSIS, 2023 303
11.4.1 RANKING OF KEY MARKET PLAYERS 306
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 306
11.5.1 STARS 306
11.5.2 EMERGING LEADERS 306
11.5.3 PERVASIVE PLAYERS 307
11.5.4 PARTICIPANTS 307
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 308
11.5.5.1 Company footprint 308
11.5.5.2 Component footprint 309
11.5.5.3 Application footprint 310
11.5.5.4 End-user footprint 311
11.5.5.5 Region footprint 312
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 313
11.6.1 PROGRESSIVE COMPANIES 313
11.6.2 RESPONSIVE COMPANIES 313
11.6.3 DYNAMIC COMPANIES 313
11.6.4 STARTING BLOCKS 313
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 315
11.7 COMPANY VALUATION & FINANCIAL METRICS 317
11.8 BRAND/PRODUCT COMPARISON 318
11.9 COMPETITIVE SCENARIO 319
11.9.1 PRODUCT LAUNCHES & UPGRADES 319
11.9.2 DEALS 320
11.9.3 EXPANSIONS 321
12 COMPANY PROFILES 322
12.1 KEY PLAYERS 322
12.1.1 NVIDIA CORPORATION 322
12.1.1.1 Business overview 322
12.1.1.2 Products offered 323
12.1.1.3 Recent developments 324
12.1.1.3.1 Product launches 324
12.1.1.3.2 Deals 324
12.1.1.4 MnM view 324
12.1.1.4.1 Right to win 324
12.1.1.4.2 Strategic choices 325
12.1.1.4.3 Weaknesses & competitive threats 325
12.1.2 ILLUMINA, INC. 326
12.1.2.1 Business overview 326
12.1.2.2 Products offered 327
12.1.2.3 Recent developments 328
12.1.2.3.1 Product launches 328
12.1.2.3.2 Deals 329
12.1.2.4 MnM view 330
12.1.2.4.1 Right to win 330
12.1.2.4.2 Strategic choices 330
12.1.2.4.3 Weaknesses & competitive threats 330
12.1.3 EXSCIENTIA 331
12.1.3.1 Business overview 331
12.1.3.2 Products offered 332
12.1.3.3 Recent developments 332
12.1.3.3.1 Product launches 332
12.1.3.3.2 Deals 332
12.1.3.3.3 Other developments 334
12.1.3.4 MnM view 335
12.1.3.4.1 Right to win 335
12.1.3.4.2 Strategic choices 335
12.1.3.4.3 Weaknesses & competitive threats 335
12.1.4 SCHRÖDINGER, INC. 336
12.1.4.1 Business overview 336
12.1.4.2 Products offered 337
12.1.4.3 Recent developments 338
12.1.4.3.1 Product upgrades 338
12.1.4.3.2 Deals 338
12.1.5 RECURSION PHARMACEUTICALS, INC. 340
12.1.5.1 Business overview 340
12.1.5.2 Products offered 341
12.1.5.3 Recent developments 341
12.1.5.3.1 Deals 341
12.1.5.3.2 Expansions 342
12.1.6 SOPHIA GENETICS 343
12.1.6.1 Business overview 343
12.1.6.2 Products offered 344
12.1.6.3 Recent developments 344
12.1.6.3.1 Product launches 344
12.1.6.3.2 Deals 345
12.1.7 PREDICTIVE ONCOLOGY 347
12.1.7.1 Business overview 347
12.1.7.2 Products offered 348
12.1.7.3 Recent developments 348
12.1.7.3.1 Product launches 348
12.1.7.3.2 Deals 348
12.1.8 BENEVOLENTAI 349
12.1.8.1 Business overview 349
12.1.8.2 Products offered 350
12.1.8.3 Recent developments 350
12.1.8.3.1 Deals 350
12.1.9 EUROFINS DISCOVERY 351
12.1.9.1 Business overview 351
12.1.9.2 Products offered 352
12.1.9.3 Recent developments 352
12.1.9.3.1 Product launches 352
12.1.9.3.2 Deals 352
12.1.9.3.3 Expansions 354
12.1.10 XTALPI INC. 355
12.1.10.1 Business overview 355
12.1.10.2 Products offered 356
12.1.10.3 Recent developments 356
12.1.10.3.1 Deals 356
12.1.11 DNANEXUS, INC. 358
12.1.11.1 Business overview 358
12.1.11.2 Products offered 358
12.1.11.3 Recent developments 359
12.1.11.3.1 Deals 359
12.1.11.3.2 Other developments 361
12.1.12 NUMEDII, INC. 362
12.1.12.1 Business overview 362
12.1.12.2 Products offered 362
12.1.13 BPGBIO, INC. 363
12.1.13.1 Business overview 363
12.1.13.2 Products offered 363
12.1.13.3 Recent developments 364
12.1.13.3.1 Deals 364
12.1.14 IKTOS. 365
12.1.14.1 Business overview 365
12.1.14.2 Products offered 365
12.1.14.3 Recent developments 365
12.1.14.3.1 Deals 365
12.1.15 INSILICO MEDICINE 366
12.1.15.1 Business overview 366
12.1.15.2 Products offered 366
12.1.16 LOGICA 367
12.1.16.1 Business overview 367
12.1.16.2 Products offered 367
12.1.17 AMERICAN CHEMICAL SOCIETY 368
12.1.17.1 Business overview 368
12.1.17.2 Products offered 368
12.1.18 AGANITHA AI INC. 369
12.1.18.1 Business overview 369
12.1.18.2 Products offered 369
12.1.18.3 Recent developments 370
12.1.18.3.1 Deals 370
12.2 START-UP/SME PLAYERS 371
12.2.1 VERISIM LIFE 371
12.2.2 VALO HEALTH 371
12.2.3 TEMPUS AI, INC. 372
12.2.4 LIFEBIT BIOTECH LTD. 373
12.2.5 GENOOX 373
12.2.6 DATA4CURE, INC. 374
12.2.7 DEEP GENOMICS 374
13 APPENDIX 375
13.1 DISCUSSION GUIDE 375
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 382
13.3 CUSTOMIZATION OPTIONS 384
13.4 RELATED REPORTS 384
13.5 AUTHOR DETAILS 385
LIST OF TABLES
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 41
TABLE 2 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN AI IN BIOTECHNOLOGY MARKET (2021−2024) 65
TABLE 3 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 76
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN BIOTECHNOLOGY MARKET, 2021–2024 85
TABLE 9 AI IN BIOTECHNOLOGY MARKET: INDICATIVE PRICING, BY DRUG DISCOVERY PROCESS 90
TABLE 10 AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES & EVENTS, 2024–2025 91
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%) 92
TABLE 12 KEY BUYING CRITERIA FOR TOP 3 END USERS 93
TABLE 13 UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET 95
TABLE 14 END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET 96
TABLE 15 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 103
TABLE 16 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION,
2022–2029 (USD MILLION) 104
TABLE 17 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION,
2022–2029 (USD MILLION) 105
TABLE 18 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION,
2022–2029 (USD MILLION) 106
TABLE 19 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 106
TABLE 20 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION,
2022–2029 (USD MILLION) 107
TABLE 21 AI IN BIOTECHNOLOGY MARKET FOR CONSULTING SERVICES, BY REGION,
2022–2029 (USD MILLION) 107
TABLE 22 AI IN BIOTECHNOLOGY MARKET FOR IMPLEMENTATION SERVICES & ONGOING
IT SUPPORT, BY REGION, 2022–2029 (USD MILLION) 108
TABLE 23 AI IN BIOTECHNOLOGY MARKET FOR TRAINING & EDUCATION SERVICES,
BY REGION, 2022–2029 (USD MILLION) 109
TABLE 24 AI IN BIOTECHNOLOGY MARKET FOR POST-SALES & MAINTENANCE SERVICES,
BY REGION, 2022–2029 (USD MILLION) 110
TABLE 25 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 112
TABLE 26 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 113
TABLE 27 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS,
BY REGION, 2022–2029 (USD MILLION) 114
TABLE 28 EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY 114
TABLE 29 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 115
TABLE 30 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY REGION,
2022–2029 (USD MILLION) 115
TABLE 31 AI IN BIOTECHNOLOGY MARKET FOR MOLECULAR DESIGN & OPTIMIZATION,
BY REGION, 2022–2029 (USD MILLION) 116
TABLE 32 AI IN BIOTECHNOLOGY MARKET FOR BIOMARKER DISCOVERY, BY REGION,
2022–2029 (USD MILLION) 116
TABLE 33 AI IN BIOTECHNOLOGY MARKET FOR STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING, BY REGION, 2022–2029 (USD MILLION) 117
TABLE 34 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE,
2022–2029 (USD MILLION) 118
TABLE 35 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY REGION,
2022–2029 (USD MILLION) 118
TABLE 36 AI IN BIOTECHNOLOGY MARKET FOR TRIAL DESIGN, BY REGION,
2022–2029 (USD MILLION) 119
TABLE 37 AI IN BIOTECHNOLOGY MARKET FOR SITE SELECTION, BY REGION,
2022–2029 (USD MILLION) 120
TABLE 38 AI IN BIOTECHNOLOGY MARKET FOR RECRUITMENT, BY REGION,
2022–2029 (USD MILLION) 120
TABLE 39 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DATA ASSESSMENT, BY REGION, 2022–2029 (USD MILLION) 121
TABLE 40 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE TOXICITY & RISK MONITORING, BY REGION, 2022–2029 (USD MILLION) 122
TABLE 41 AI IN BIOTECHNOLOGY MARKET FOR MONITORING & DRUG ADHERENCE,
BY REGION, 2022–2029 (USD MILLION) 122
TABLE 42 AI IN BIOTECHNOLOGY MARKET FOR REAL-WORLD EVIDENCE (RWE) ANALYSIS,
BY REGION, 2022–2029 (USD MILLION) 123
TABLE 43 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE FUNCTIONS,
BY REGION, 2022–2029 (USD MILLION) 124
TABLE 44 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 125
TABLE 45 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 125
TABLE 46 AI IN BIOTECHNOLOGY MARKET FOR SUPPLY CHAIN PLANNING, BY REGION, 2022–2029 (USD MILLION) 126
TABLE 47 AI IN BIOTECHNOLOGY MARKET FOR INVENTORY MANAGEMENT, BY REGION, 2022–2029 (USD MILLION) 127
TABLE 48 AI IN BIOTECHNOLOGY MARKET FOR LOGISTICS OPTIMIZATION, BY REGION,
2022–2029 (USD MILLION) 127
TABLE 49 AI IN BIOTECHNOLOGY MARKET FOR DEMAND FORECASTING, BY REGION,
2022–2029 (USD MILLION) 128
TABLE 50 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE MAINTENANCE, BY REGION, 2022–2029 (USD MILLION) 129
TABLE 51 AI IN BIOTECHNOLOGY MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 129
TABLE 52 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 130
TABLE 53 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS,
BY REGION, 2022–2029 (USD MILLION) 130
TABLE 54 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH COORDINATION, BY REGION,
2022–2029 (USD MILLION) 131
TABLE 55 AI IN BIOTECHNOLOGY MARKET FOR PATIENT ENGAGEMENT, BY REGION,
2022–2029 (USD MILLION) 132
TABLE 56 AI IN BIOTECHNOLOGY MARKET FOR MARKETING OPERATIONS, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 57 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE PRICING, BY REGION,
2022–2029 (USD MILLION) 133
TABLE 58 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 134
TABLE 59 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 134
TABLE 60 AI IN BIOTECHNOLOGY MARKET FOR MEDICATION ADHERENCE, BY REGION, 2022–2029 (USD MILLION) 135
TABLE 61 AI IN BIOTECHNOLOGY MARKET FOR ADVERSE EVENT REPORTING, BY REGION, 2022–2029 (USD MILLION) 135
TABLE 62 AI IN BIOTECHNOLOGY MARKET FOR PATIENT MONITORING, BY REGION,
2022–2029 (USD MILLION) 136
TABLE 63 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 64 AI IN BIOTECHNOLOGY MARKET FOR PATIENT SUPPORT PROGRAMS, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 65 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 138
TABLE 66 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY REGION,
2022–2029 (USD MILLION) 138
TABLE 67 AI IN BIOTECHNOLOGY MARKET FOR RISK MANAGEMENT, BY REGION,
2022–2029 (USD MILLION) 139
TABLE 68 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022–2029 (USD MILLION) 140
TABLE 69 AI IN BIOTECHNOLOGY MARKET FOR SALES FORCE OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION) 140
TABLE 70 AI IN BIOTECHNOLOGY MARKET FOR OTHER CORPORATE FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 141
TABLE 71 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 143
TABLE 72 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE,
2022–2029 (USD MILLION) 143
TABLE 73 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2022–2029 (USD MILLION) 144
TABLE 74 AI IN BIOTECHNOLOGY MARKET FOR PUBLIC CLOUD, BY REGION,
2022–2029 (USD MILLION) 145
TABLE 75 AI IN BIOTECHNOLOGY MARKET FOR PRIVATE CLOUD, BY REGION,
2022–2029 (USD MILLION) 146
TABLE 76 AI IN BIOTECHNOLOGY MARKET FOR MULTI-CLOUD, BY REGION,
2022–2029 (USD MILLION) 147
TABLE 77 AI IN BIOTECHNOLOGY MARKET FOR HYBRID CLOUD, BY REGION,
2022–2029 (USD MILLION) 148
TABLE 78 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISE SOLUTIONS, BY REGION,
2022–2029 (USD MILLION) 149
TABLE 79 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 151
TABLE 80 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION) 152
TABLE 81 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 153
TABLE 82 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2022–2029 (USD MILLION) 154
TABLE 83 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022–2029 (USD MILLION) 155
TABLE 84 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2022–2029 (USD MILLION) 156
TABLE 85 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION) 158
TABLE 86 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 160
TABLE 87 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 160
TABLE 88 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 160
TABLE 89 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 161
TABLE 90 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 91 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY,
BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 92 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 93 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 94 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 95 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 163
TABLE 96 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 97 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 164
TABLE 98 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 99 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 165
TABLE 100 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 166
TABLE 101 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 166
TABLE 102 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 167
TABLE 103 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 104 US: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 167
TABLE 105 US: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 106 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 107 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 108 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 109 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 110 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 170
TABLE 111 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 112 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 171
TABLE 113 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 172
TABLE 114 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 172
TABLE 115 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 173
TABLE 116 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 117 CANADA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 173
TABLE 118 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 119 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 120 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 121 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 122 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 123 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 176
TABLE 124 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 125 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 177
TABLE 126 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 178
TABLE 127 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 178
TABLE 128 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 179
TABLE 129 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 179
TABLE 130 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 180
TABLE 131 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 180
TABLE 132 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 133 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 134 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 135 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 136 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 137 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 183
TABLE 138 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 139 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 184
TABLE 140 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 185
TABLE 141 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 185
TABLE 142 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 186
TABLE 143 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 144 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 145 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT,
BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 146 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 147 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 188
TABLE 148 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 188
TABLE 149 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 150 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 189
TABLE 151 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 152 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 190
TABLE 153 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 190
TABLE 154 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 191
TABLE 155 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 191
TABLE 156 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 157 UK: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 192
TABLE 158 UK: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 159 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 160 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 161 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 162 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 163 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 194
TABLE 164 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 165 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 195
TABLE 166 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 196
TABLE 167 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 196
TABLE 168 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 197
TABLE 169 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 170 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 197
TABLE 171 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 172 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 173 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 174 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 175 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 176 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 200
TABLE 177 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 178 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 201
TABLE 179 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 202
TABLE 180 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 202
TABLE 181 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 203
TABLE 182 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 183 ITALY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 203
TABLE 184 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 185 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 186 ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 205
TABLE 187 ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 205
TABLE 188 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 189 ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 206
TABLE 190 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 191 ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 207
TABLE 192 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 207
TABLE 193 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 208
TABLE 194 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 208
TABLE 195 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 196 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 209
TABLE 197 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 198 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 199 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 200 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 201 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 202 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 211
TABLE 203 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 204 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 212
TABLE 205 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 213
TABLE 206 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 207 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 214
TABLE 208 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 214
TABLE 209 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY,
BY TYPE, 2022–2029 (USD MILLION) 214
TABLE 210 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 211 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 212 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 213 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 216
TABLE 214 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 215 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 217
TABLE 216 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 217 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 218
TABLE 218 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 220
TABLE 219 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 220
TABLE 220 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 221
TABLE 221 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 221
TABLE 222 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 222
TABLE 223 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 222
TABLE 224 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT,
BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 225 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 226 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 227 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 224
TABLE 228 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 229 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 225
TABLE 230 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 231 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 226
TABLE 232 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 227
TABLE 233 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 227
TABLE 234 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 228
TABLE 235 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 236 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 228
TABLE 237 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 238 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 239 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 240 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 241 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 242 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 231
TABLE 243 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 244 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 232
TABLE 245 CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 233
TABLE 246 CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 233
TABLE 247 CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 234
TABLE 248 CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 249 CHINA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 234
TABLE 250 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 251 CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 252 CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 253 CHINA: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 254 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 255 CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 237
TABLE 256 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 257 CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 238
TABLE 258 INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 239
TABLE 259 INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 239
TABLE 260 INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 240
TABLE 261 INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 240
TABLE 262 INDIA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 240
TABLE 263 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 264 INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 265 INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 242
TABLE 266 INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 242
TABLE 267 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 268 INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 243
TABLE 269 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 270 INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 244
TABLE 271 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 245
TABLE 272 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 245
TABLE 273 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 246
TABLE 274 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 246
TABLE 275 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 246
TABLE 276 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT,
BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 277 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 278 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 279 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 248
TABLE 280 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 249
TABLE 281 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 249
TABLE 282 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 249
TABLE 283 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 250
TABLE 284 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 251
TABLE 285 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES,
BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 286 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 252
TABLE 287 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 288 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY,
BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 289 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 253
TABLE 290 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 253
TABLE 291 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 254
TABLE 292 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 254
TABLE 293 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 294 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 255
TABLE 295 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 296 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 256
TABLE 297 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 257
TABLE 298 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 257
TABLE 299 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 257
TABLE 300 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 258
TABLE 301 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 258
TABLE 302 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 258
TABLE 303 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT,
BY TYPE, 2022–2029 (USD MILLION) 259
TABLE 304 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 259
TABLE 305 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 306 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 260
TABLE 307 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 308 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 261
TABLE 309 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 310 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 262
TABLE 311 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 263
TABLE 312 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 263
TABLE 313 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 264
TABLE 314 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 264
TABLE 315 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 264
TABLE 316 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 265
TABLE 317 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 265
TABLE 318 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 266
TABLE 319 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 266
TABLE 320 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 267
TABLE 321 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 267
TABLE 322 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 267
TABLE 323 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 268
TABLE 324 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 269
TABLE 325 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 269
TABLE 326 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 270
TABLE 327 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 270
TABLE 328 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 270
TABLE 329 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 271
TABLE 330 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 271
TABLE 331 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 332 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 333 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 334 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 273
TABLE 335 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 336 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 274
TABLE 337 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 275
TABLE 338 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION) 275
TABLE 339 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 276
TABLE 340 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 276
TABLE 341 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 276
TABLE 342 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 277
TABLE 343 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 277
TABLE 344 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 278
TABLE 345 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 278
TABLE 346 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 279
TABLE 347 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 279
TABLE 348 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 279
TABLE 349 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 280
TABLE 350 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 281
TABLE 351 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 281
TABLE 352 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES,
BY TYPE, 2022–2029 (USD MILLION) 281
TABLE 353 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 282
TABLE 354 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 282
TABLE 355 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 282
TABLE 356 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 283
TABLE 357 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 283
TABLE 358 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 284
TABLE 359 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 284
TABLE 360 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 361 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 285
TABLE 362 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 363 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 286
TABLE 364 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 288
TABLE 365 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 288
TABLE 366 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 289
TABLE 367 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 289
TABLE 368 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 289
TABLE 369 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 290
TABLE 370 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 290
TABLE 371 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 291
TABLE 372 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 291
TABLE 373 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 292
TABLE 374 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 292
TABLE 375 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 292
TABLE 376 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 293
TABLE 377 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 294
TABLE 378 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION) 294
TABLE 379 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 295
TABLE 380 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 295
TABLE 381 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 295
TABLE 382 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 296
TABLE 383 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 296
TABLE 384 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 297
TABLE 385 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 297
TABLE 386 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 298
TABLE 387 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET,
BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 298
TABLE 388 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR
CLOUD-BASED SOLUTIONS MODE, BY TYPE, 2022–2029 (USD MILLION) 298
TABLE 389 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 299
TABLE 390 AI IN BIOTECHNOLOGY: DEGREE OF COMPETITION 304
TABLE 391 AI IN BIOTECHNOLOGY MARKET: OFFERING FOOTPRINT 309
TABLE 392 AI IN BIOTECHNOLOGY MARKET: FUNCTION FOOTPRINT 310
TABLE 393 AI IN BIOTECHNOLOGY MARKET: END-USER FOOTPRINT 311
TABLE 394 AI IN BIOTECHNOLOGY: REGION FOOTPRINT 312
TABLE 395 AI IN BIOTECHNOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES 315
TABLE 396 AI IN BIOTECHNOLOGY: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 316
TABLE 397 AI IN BIOTECHNOLOGY MARKET: PRODUCT LAUNCHES & UPGRADES,
JANUARY 2021–AUGUST 2024 319
TABLE 398 AI IN BIOTECHNOLOGY MARKET: DEALS, JANUARY 2021–AUGUST 2024 320
TABLE 399 AI IN BIOTECHNOLOGY MARKET: EXPANSIONS, JANUARY 2021–AUGUST 2024 321
TABLE 400 NVIDIA CORPORATION: COMPANY OVERVIEW 322
TABLE 401 NVIDIA CORPORATION: PRODUCTS OFFERED 323
TABLE 402 NVIDIA CORPORATION: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024 324
TABLE 403 NVIDIA CORPORATION: DEALS, JANUARY 2021−AUGUST 2024 324
TABLE 404 ILLUMINA, INC.: COMPANY OVERVIEW 326
TABLE 405 ILLUMINA, INC.: PRODUCTS OFFERED 327
TABLE 406 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024 328
TABLE 407 ILLUMINA, INC.: DEALS, JANUARY 2021−AUGUST 2024 329
TABLE 408 EXSCIENTIA: COMPANY OVERVIEW 331
TABLE 409 EXSCIENTIA: PRODUCTS OFFERED 332
TABLE 410 EXSCIENTIA: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024 332
TABLE 411 EXSCIENTIA: DEALS, JANUARY 2021−AUGUST 2024 332
TABLE 412 EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021−AUGUST 2024 334
TABLE 413 SCHRÖDINGER, INC.: COMPANY OVERVIEW 336
TABLE 414 SCHRÖDINGER, INC.: PRODUCTS OFFERED 337
TABLE 415 SCHRÖDINGER, INC.: PRODUCT UPGRADES, JANUARY 2021−AUGUST 2024 338
TABLE 416 SCHRÖDINGER, INC.: DEALS, JANUARY 2021−AUGUST 2024 338
TABLE 417 RECURSION PHARMACEUTICALS, INC.: COMPANY OVERVIEW 340
TABLE 418 RECURSION PHARMACEUTICALS, INC.: PRODUCTS OFFERED 341
TABLE 419 RECURSION PHARMACEUTICALS, INC.: DEALS, JANUARY 2021−AUGUST 2024 341
TABLE 420 RECURSION PHARMACEUTICALS, INC.: EXPANSIONS,
JANUARY 2021−AUGUST 2024 342
TABLE 421 SOPHIA GENETICS: COMPANY OVERVIEW 343
TABLE 422 SOPHIA GENETICS: PRODUCTS OFFERED 344
TABLE 423 SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024 344
TABLE 424 SOPHIA GENETICS: DEALS, JANUARY 2021−AUGUST 2024 345
TABLE 425 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW 347
TABLE 426 PREDICTIVE ONCOLOGY: PRODUCTS OFFERED 348
TABLE 427 PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024 348
TABLE 428 PREDICTIVE ONCOLOGY: DEALS, JANUARY 2021−AUGUST 2024 348
TABLE 429 BENEVOLENTAI: COMPANY OVERVIEW 349
TABLE 430 BENEVOLENTAI: PRODUCTS OFFERED 350
TABLE 431 BENEVOLENTAI: DEALS, JANUARY 2021−AUGUST 2024 350
TABLE 432 EUROFINS DISCOVERY: COMPANY OVERVIEW 351
TABLE 433 EUROFINS DISCOVERY: PRODUCTS OFFERED 352
TABLE 434 EUROFINS DISCOVERY: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024 352
TABLE 435 EUROFINS DISCOVERY: DEALS, JANUARY 2021−AUGUST 2024 352
TABLE 436 EUROFINS DISCOVERY: EXPANSIONS, JANUARY 2021−AUGUST 2024 354
TABLE 437 XTALPI INC.: COMPANY OVERVIEW 355
TABLE 438 XTALPI INC.: PRODUCTS OFFERED 356
TABLE 439 XTALPI INC.: DEALS, JANUARY 2021−AUGUST 2024 356
TABLE 440 DNANEXUS, INC.: COMPANY OVERVIEW 358
TABLE 441 DNANEXUS, INC.: PRODUCTS OFFERED 358
TABLE 442 DNANEXUS, INC.: DEALS, JANUARY 2021−AUGUST 2024 359
TABLE 443 DNANEXUS, INC: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024 361
TABLE 444 NUMEDII, INC.: COMPANY OVERVIEW 362
TABLE 445 NUMEDII, INC.: PRODUCTS OFFERED 362
TABLE 446 BPGBIO, INC.: COMPANY OVERVIEW 363
TABLE 447 BPGBIO, INC.: PRODUCTS OFFERED 363
TABLE 448 BPGBIO, INC.: DEALS, JANUARY 2021−AUGUST 2024 364
TABLE 449 IKTOS: COMPANY OVERVIEW 365
TABLE 450 IKTOS: PRODUCTS OFFERED 365
TABLE 451 IKTOS: DEALS, JANUARY 2021−AUGUST 2024 365
TABLE 452 INSILICO MEDICINE: COMPANY OVERVIEW 366
TABLE 453 INSILICO MEDICINE: PRODUCTS OFFERED 366
TABLE 454 LOGICA: COMPANY OVERVIEW 367
TABLE 455 LOGICA: PRODUCTS OFFERED 367
TABLE 456 AMERICAN CHEMICAL SOCIETY: COMPANY OVERVIEW 368
TABLE 457 AMERICAN CHEMICAL SOCIETY: PRODUCTS OFFERED 368
TABLE 458 AGANITHA AI INC.: COMPANY OVERVIEW 369
TABLE 459 AGANITHA AI INC.: PRODUCTS OFFERED 369
TABLE 460 AGANITHA AI INC.: DEALS, JANUARY 2021−AUGUST 2024 370
LIST OF FIGURES
FIGURE 1 AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE 38
FIGURE 2 RESEARCH DESIGN 43
FIGURE 3 PRIMARY SOURCES 46
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 48
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 49
FIGURE 6 TOP-DOWN APPROACH 50
FIGURE 7 AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS 51
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 52
FIGURE 9 DATA TRIANGULATION 53
FIGURE 10 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 56
FIGURE 11 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2024 VS. 2029 (USD MILLION) 57
FIGURE 12 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2024 VS. 2029 (USD MILLION) 57
FIGURE 13 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 58
FIGURE 14 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHICAL SNAPSHOT 59
FIGURE 15 GROWING FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET 60
FIGURE 16 NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET DURING FORECAST PERIOD 61
FIGURE 17 PHARMACEUTICAL COMPANIES IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 62
FIGURE 18 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63
FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 63
FIGURE 20 AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 64
FIGURE 21 AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS 71
FIGURE 22 AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS 74
FIGURE 23 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 75
FIGURE 24 PATENT PUBLICATION TRENDS IN AI IN BIOTECHNOLOGY MARKET, 2015–2024 83
FIGURE 25 PATENT ANALYSIS OF AI IN BIOTECHNOLOGY MARKET,
JANUARY 2015–AUGUST 2024 84
FIGURE 26 EVOLUTION OF AI IN BIOTECHNOLOGY MARKET 88
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS 92
FIGURE 28 KEY BUYING CRITERIA FOR TOP 3 END USERS 93
FIGURE 29 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
FIGURE 30 AI IN BIOTECHNOLOGY MARKET: INVESTMENT & FUNDING SCENARIO 96
FIGURE 31 MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS 97
FIGURE 32 NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS 113
FIGURE 33 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT 159
FIGURE 34 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT 219
FIGURE 35 KEY DEVELOPMENTS OF MAJOR PLAYERS BETWEEN
JANUARY 2021 AND JUNE 2024 301
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET,
2019–2023 (USD BILLION) 302
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2023) 303
FIGURE 38 RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2023 306
FIGURE 39 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 307
FIGURE 40 AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT 308
FIGURE 41 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX
(START-UPS/SMES), 2023 314
FIGURE 42 EV/EBITDA OF KEY VENDORS 317
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
AI IN BIOTEHNOLOGY SOLUTION VENDORS 317
FIGURE 44 AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 318
FIGURE 45 NVIDIA CORPORATION: COMPANY SNAPSHOT (2024) 323
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) 327
FIGURE 47 EXSCIENTIA: COMPANY SNAPSHOT (2023) 331
FIGURE 48 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2023) 337
FIGURE 49 RECURSION PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023) 340
FIGURE 50 SOPHIA GENETICS: COMPANY SNAPSHOT (2022) 343
FIGURE 51 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT (2023) 347
FIGURE 52 BENEVOLENTAI: COMPANY SNAPSHOT (2023) 349
FIGURE 53 EUROFINS DISCOVERY: COMPANY SNAPSHOT (2023) 351
FIGURE 54 XTALPI INC.: COMPANY SNAPSHOT (2023) 355
